Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Zeo ScientifiX, Inc.

Get SEC filing alerts via email and in your feed for Zeo ScientifiX, Inc.

ZEOX

Zeo ScientifiX, Inc.

About Zeo ScientifiX, Inc.

Zeo Scientifix, Inc. is a clinical-stage biopharmaceutical company specializing in regenerative medicine and biologics derived from perinatal sources and blood. Its core products include extracellular vesicle therapies like Zofin and autologous biologics such as Patient Pure X. The company develops innovative treatments for degenerative diseases, aesthetic applications, and pain management, operating research labs and pursuing FDA approvals to expand its market globally.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Zeo ScientifiX, Inc.

1
1
Zeo ScientifiX, Inc. Zeo ScientifiX Reports 32.7% Revenue Increase to $1.446 Million, Net Loss Improves

Via official filing (AI summary) | 3 months ago | 0 comments

2
1
Zeo ScientifiX, Inc. Zeo ScientifiX Reports 12.5% Revenue Growth, Faces Increased Net Loss and Financial Challenges

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Zeo ScientifiX, Inc. Zeo ScientifiX Reports 19.7% Revenue Growth but Increases Net Loss in Latest Quarter

Via official filing (AI summary) | 9 months ago | 0 comments

4
1
Zeo ScientifiX, Inc. Zeo ScientifiX Reports Mixed Financial Results for Nine Months Ended July 31, 2024

Via official filing (AI summary) | over 1 year ago | 0 comments